Real-World, Digital-First GLP-1 Receptor Agonist Treatment for Women

Category	Detail
Condition	Clinical topic addressed by the source article: Real-World, Digital-First GLP-1 Receptor Agonist Treatment for Women
Key Mechanisms	The article reports that GLP-1RAs and other incretin-based treatments produced weight reduction and improved cardiometabolic risk factors in large randomized trials; it describes visceral and ectopic fat as contributing to cardiometabolic disease pathogenesis.
Target Population	Population described in the source article.
Care Setting	A remote, community-based digital–clinical hybrid program with structured onboarding, baseline blood testing, clinical review, monthly questionnaires, weekly live-video check-ins, and clinician-led dose titration.

The analytic cohort comprised 8,127 women prescribed and dispatched GLP-1RA therapy after eligibility screening, laboratory completion, and clinical review.
Baseline mean weight was 104.2 kg and mean BMI was 38.2 kg/m²; 95.5% met criteria for class I–III obesity.
The program required monthly questionnaires before refill approval and included weekly live-video check-ins with trained proctors.
Monthly clinician-led assessments supported individualized, response-guided dose titration rather than automatic escalation.

The supplied source excerpt does not report the initiation dose, treatment outcomes, or subsequent dose distributions.

Program feature: structured onboarding collected clinical history, anthropometric measures, medication exposure, and contraindication information.
Program feature: baseline blood testing and clinical review preceded treatment initiation.
Program feature: regular clinician assessment supported individualized dose titration rather than automatic escalation.
Program feature: remote prescribing was paired with structured follow-up, supervised measurement checks, and accessible side-effect education.